Lung cancer

• 1. Introduction

  ›

  Lung cancer begins with a single cell in the airways whose DNA has been damaged, often by cigarette smoke or inhaled chemicals. That cell gains the ability to multiply unchecked, and a tumor grows. Left untreated, it spreads through the lung, damages how the lung works, and eventually reaches other parts of the body. The strange thing is how quietly it starts. Early lung cancer often has no symptoms at all, detectable only by medical imaging. Today it is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 and 1.8 million deaths. Yet before the 20th century it was a rare disease. How did a once-uncommon illness become the leading cause of cancer death? Why do only around 20% of those diagnosed survive five years? And how did doctors, miners, and tobacco executives all play a part in the story of how this disease was understood?

• 2. The Body Under Siege

  ›

  Around one in four people with lung cancer cough up blood, ranging from small streaks in the sputum to large amounts. About half experience shortness of breath, and between 25% and 50% feel a dull, persistent chest pain that stays in the same spot over time. Some lose their appetite, lose weight, or develop fever and night sweats. Tumors in the thorax can press on or disrupt the body in specific ways. They can obstruct the trachea, compress the esophagus to make swallowing hard, or disrupt the nerves of the larynx to cause hoarseness. A tumor at the top of the lung, called a Pancoast tumor, can produce shoulder pain that radiates down the little-finger side of the arm and even destroy the topmost ribs. About one in three people diagnosed have symptoms caused by spread to sites beyond the lungs. The disease most commonly reaches the brain, bones, liver, and adrenal glands, each producing its own signs, from seizures to bone fractures. Stranger still, lung tumors often release body-altering hormones that trigger what are called paraneoplastic syndromes. The most common is hypercalcemia, high blood calcium, driven by overproduction of parathyroid hormone-related protein. About one in three people develop nail clubbing, and a rarer autoimmune effect, Lambert-Eaton myasthenic syndrome, causes muscle weakness. These hidden hormonal effects are sometimes the first clue that something is wrong.

• 3. Reading The Tumor

  ›

  A definitive diagnosis requires a biopsy, a sample of the suspected tissue examined under a microscope by a pathologist for cancer cells. Before that, imaging maps the problem. Many primary care providers start with a chest X-ray to look for a mass, which may reveal lung collapse, pneumonia, or fluid around the lung, though some tumors stay invisible to X-ray. A CT scan then shows the size and location of tumors. The biopsy itself can often be taken with minimally invasive tools, such as a fiberoptic bronchoscope that retrieves tissue, fine needle aspiration, or an imaging-guided needle through the skin. For those who cannot undergo a standard procedure, a liquid biopsy of body fluid may capture circulating tumor DNA. What the pathologist sees decides everything that follows. Around 15% of cases are small-cell lung cancer, whose cells appear small with ill-defined boundaries and distinctive granular nuclei. The other 85% are non-small-cell lung cancers, split into three types. Nearly 40% of all lung cancers are adenocarcinomas, whose cells grow in three-dimensional clumps and may produce mucin. About 30% are squamous-cell carcinomas, often near large airways, with sheets of cells and layers of keratin. Less than 10% are large-cell carcinomas. To confirm the type, biopsies are often stained by immunohistochemistry; small-cell tumors carry neuroendocrine markers like chromogranin and synaptophysin, while adenocarcinomas tend to express Napsin-A and TTF-1. The cell of origin sets the entire course of treatment, because different tumors progress and respond to drugs differently.

• 4. Mapping The Spread

  ›

  Lung cancer staging measures how far the disease has spread from its source, and it shapes both treatment and prognosis. Small-cell lung cancer uses a simple split. Around a third of people are diagnosed at the limited stage, with cancer confined to one side of the chest, within a single radiotherapy field. The other two thirds reach the extensive stage, spread to both sides or beyond. Non-small-cell lung cancer, and sometimes small-cell, uses the more detailed TNM system from the American Joint Committee on Cancer, scoring the tumor, the lymph nodes, and distant metastases. Tumor size is graded in centimeters. A T1 tumor is no more than 3 cm across; a T4 tumor is larger than 7 cm or invades the mediastinum, heart, trachea, esophagus, or spine. Lymph node spread climbs from N0, no nodes involved, to N3, nodes on the opposite side of the lung. Metastases run from M0, none, to M1c, two or more outside the chest. These scores combine into stage groups, from stage I for the smallest, contained tumors to stage IV for cancer that has metastasized. That single grouping carries the weight of a prognosis.

• 5. Catching It Early

  ›

  Low-dose CT scans can find tumors before symptoms appear, and the payoff is measurable. Regular low-dose CT in people at high risk reduces total lung cancer deaths by as much as 20%. Screening is not free of harm. A false positive can lead to unnecessary testing, invasive procedures, and distress, and there is a rare risk of radiation-induced cancer. The thresholds reflect that balance. The United States Preventive Services Task Force recommends yearly low-dose CT for people between 55 and 80 with a smoking history of at least 30 pack-years. The Canadian Task Force for Preventive Health sets a similar bar, recommending screening for current or former smokers with more than 30 pack-years who are between 55 and 74. The European Commission has recommended extending screening across the European Union to include low-dose CT for current or previous smokers. One catch makes the work harder. In screening studies, as many as 30% of those screened have a lung nodule, and the majority turn out to be benign, caused by conditions such as hamartomas or infections like tuberculosis.

• 6. The Arsenal

  ›

  Treatment depends on the cell type, the spread, and the person's health, and the options have multiplied. For limited-stage small-cell lung cancer, guidelines recommend four to six cycles of a platinum-based drug, cisplatin or carboplatin, combined with etoposide or irinotecan, alongside thoracic radiation. This first-line therapy causes remission in up to 80% of those who receive it, yet most people relapse with chemotherapy-resistant disease. For early non-small-cell lung cancer, surgery often comes first, removing the affected lobe of the lung, or an entire lung in a pneumonectomy when needed. The most precise weapons target the genetics of the cancer itself. Up to 30% of tumors have mutations in the EGFR gene, treatable with inhibitors like osimertinib, which is known to be superior to erlotinib and gefitinib. Up to 7% carry a hyperactive ALK protein, met by drugs such as crizotinib and the third-generation lorlatinib. Rarer targets include BRAF, ROS1, NTRK, and RET, each with its own matched drug. For tumors with no targetable mutation, doctors turn to immune checkpoint inhibitors, which stop cancer cells from inactivating immune T cells. Drugs like pembrolizumab work best against tumors that express the protein PD-L1. Even with this growing arsenal, the gains can be small; adding an immune checkpoint inhibitor to chemotherapy in extensive-stage small-cell disease extends the average lifespan by around 2 months.

• 7. Comfort And Endings

  ›

  Up to 92% of those with lung cancer report pain, from tissue damage at the tumor site or from damaged nerves. The World Health Organization built a three-tiered system to manage it, starting with acetaminophen or an anti-inflammatory for mild pain and moving to opioid painkillers for the third of people in moderate or severe pain. Breathing is the other great burden. Supplemental oxygen, improved airflow, repositioning a person in bed, and low-dose morphine can all ease shortness of breath. In roughly 20% to 30% of cases, a growing tumor narrows or blocks the airway, and doctors may insert a stent, shrink the tumor with localized radiation, or physically remove the blockage by bronchoscopy. Integrating this kind of care from the moment of diagnosis does more than soothe. Palliative care introduced early improves both survival time and quality of life. Near the end of life, new symptoms appear. Some experience terminal delirium, managed with antipsychotics and low-dose sedatives. Many develop terminal secretions, pooled fluid that creates a rattling sound while breathing, reduced with anticholinergic medications. Because even non-communicative people may still feel pain, pain medications are typically continued until the time of death.

• 8. A Manufactured Doubt

  ›

  Surgeon Alton Ochsner recalled that as a Washington University medical student in 1919, his whole class was summoned to witness the autopsy of a man who had died of lung cancer, and told they might never see such a case again. Isaac Adler, writing in his 1912 book Primary Malignant Growths of the Lungs and Bronchi, called the disease among the rarest forms of illness, counting just 374 published cases. Then the evidence began to gather. Through the 1940s and early 1950s, case-control studies showed that people with lung cancer were more likely to have smoked, followed by prospective cohort studies including the first report of the British Doctors Study in 1954. A 1953 study showing that cigarette tar could cause tumors in mice reached the popular press, with features in Life and Time magazines. The industry responded. Facing public concern and falling stock prices, the CEOs of six of the largest American tobacco companies gathered in December 1953 and enlisted the public relations firm Hill and Knowlton to fund tobacco-friendly research and brand the link controversial. Their own internal research, kept secret, supported the connection. The tide turned with official voices. In 1962 the United Kingdom's Royal College of Physicians concluded that cigarette smoking causes lung cancer, prompting the United States Surgeon General to convene an advisory committee that deliberated in secret across nine sessions. Its report, published in January 1964, found that cigarette smoking far outweighs all other factors in causing lung cancer. A separate thread ran through the mines of Germany's Ore Mountains, where as early as 1500 workers developed a deadly mountain sickness, later identified as lung cancer and, in the 1950s, tied to radon. The International Agency for Research on Cancer classified radon as carcinogenic to humans in 1988, the lasting verdict of a danger first noticed five centuries earlier.